BioVersys AG (CHIX:BIOVZ) FCF Margin %: -1,563.75% (As of Dec. 2025)


CHIX:BIOVZ BioVersys AG CHIX:BIOVZ
14 GF Score
Price CHF27.10
View Full Analysis

What is BioVersys AG FCF Margin %?

BioVersys AG CHIX:BIOVZ 14 FCF Margin % is -1,563.75% as of Dec. 2025. GuruFocus rates CHIX:BIOVZ with a GF Score™ of 14/100. Among 949 Biotechnology companies, BioVersys AG ranks worse than 85.88% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioVersys AG's Free Cash Flow for the six months ended in Dec. 2025 was CHF-12.51 Mil. BioVersys AG's Revenue for the six months ended in Dec. 2025 was CHF0.80 Mil. Therefore, BioVersys AG's FCF Margin % for the quarter that ended in Dec. 2025 was -1,563.75%.

As of today, BioVersys AG's current FCF Yield % is -14.04%.

The historical rank and industry rank for BioVersys AG's FCF Margin % or its related term are showing as below:

CHIX:BIOVz' s FCF Margin % Range Over the Past 10 Years
Min: -2770.25   Med: -2770.25   Max: -2770.25
Current: -2770.25

During the past 2 years, the highest FCF Margin % of BioVersys AG was -2770.25%. The lowest was -2770.25%. And the median was -2770.25%.

CHIX:BIOVz's FCF Margin % is ranked worse than
85.88% of 949 companies
in the Biotechnology industry
Industry Median: -82.65 vs CHIX:BIOVz: -2770.25

BioVersys AG FCF Margin % Related Terms

BioVersys AG FCF Margin % Historical Data

* Premium members only.

The historical data trend for BioVersys AG's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG FCF Margin % Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
FCF Margin %
0.00 -2,770.25

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
FCF Margin % 0.00 0.00 0.00 -1,563.75

CHIX:BIOVZ vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, BioVersys AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVersys AG FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVersys AG's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BioVersys AG's FCF Margin % falls into.


CHIX:BIOVZ
14GF Score
BioVersys AG CHIX:BIOVZ
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BioVersys AG's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-22.162/0.8
=-2,770.25 %

BioVersys AG's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-12.51/0.8
=-1,563.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -1,563.75% mean?
BioVersys AG (CHIX:BIOVZ) has a FCF Margin % of -1,563.75% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BioVersys AG and its competitors. According to the industry distribution chart, BioVersys AG ranks #815 out of 949 companies in the Biotechnology industry, placing it in the top 85.9%.
Is BioVersys AG's FCF Margin % too high?
BioVersys AG's current FCF Margin % is -1,563.75%. Based on the distribution chart, BioVersys AG ranks #815 out of 949 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioVersys AG has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioVersys AG ranks #815 out of 949 companies for FCF Margin %. This places BioVersys AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BioVersys AG and its competitors. BioVersys AG's current FCF Margin % is -1,563.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (CHIX:BIOVZ) has a current FCF Margin % of -1,563.75%. The current FCF Margin % is -1,563.75%. BioVersys AG's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For BioVersys AG (CHIX:BIOVZ), the current FCF Margin % is -1,563.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges W33:GermanyBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
14GF Score

Get the complete analysis for CHIX:BIOVZ

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.10
Price